



Summit Therapeutics plc
(‘Summit’ or the ‘Company’)

Summit Therapeutics to Participate in Upcoming Investor Events

Oxford, UK, and Cambridge, MA, US, 10 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that management will participate in two upcoming investor events.

- BIO Investor Forum, Mr Glyn Edwards is speaking on the panel “Using Microbiome-Based Therapies to Improve Patient Outcomes,” 10:45am PDT, 17 October 2018 in San Francisco, CA
- BTIG Biotech Conference, 25 October 2018 in New York City

At these events, management will conduct one-on-one meetings; there will be no podium presentations.

About Summit Therapeutics

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for *C. difficile* infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit

Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)

Tel: 44 (0)1235 443 951
+1 617 225 4455

Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Tony Rawlinson

Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Broker)
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking

Tel: +44 (0)20 7496 3000

Panmure Gordon (Joint Broker)
Freddy Crossley, Corporate Finance
James Stearns, Corporate Broking

Tel: +44 (0)20 7886 2500

MSL Group (US)
Jon Siegal

Tel: +1 781 684 6557
summit@msslgroup.com

Consilium Strategic Communications (UK)
Mary-Jane Elliott / Jessica Hodgson /
Lindsey Neville

Tel: +44 (0)20 3709 5700
summit@consilium-comms.com

-END-